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The high incidence of chronic diseases in the elderly leads to increased intermittent drug therapies. The 
presence of concomitant diseases and prescriptions made out by various health professionals facilitate 
the practice of polypharmacy, the emergence of iatrogenic diseases, and therapeutic regimens that are 
inconvenient for patients. The present study was carried out among elderly patients hospitalized at the 
Hospital Care Foundation of Paraiba, Campina Grande, with the objectives of studying the consumption 
of drugs by these patients, noting the possible adverse drug reactions (ADR), drug interactions and the 
presence of high-risk drugs prescribed to this age group. The study had a descriptive and cross-sectional 
quantitative design and involved a sample of 65 patients accompanied by the Pharmacovigilance Centre 
of the hospital, from August 2009 to July 2010. Over 90% of the patients were on polypharmacy, and the 
possible ADR found were related to the gastrointestinal tract where the most frequent interactions were 
with cardiovascular drugs. Within the context of pharmacoepidemiology, pharmacists can contribute by 
improving the quality of life of patients and preventing unnecessary expense with erroneous and poorly 
evaluated treatments.
Uniterms: Elderly patients/drugs use. Polypharmacy. Drugs/adverse reactions. Drug interactions.
A elevada incidência de doenças crônicas na terceira idade induz ao aumento de terapias medicamentosas 
intermitentes. A presença de patologias concomitantes e prescrições elaboradas por diversos profissionais 
de saúde facilitam a prática da polifarmácia, surgimento de doenças iatrogênicas e esquemas terapêuticos 
pouco cômodos para o paciente. O estudo foi realizado junto aos pacientes idosos internados no Hospital 
da Fundação Assistencial da Paraíba (FAP), Campina Grande, com objetivo de estudar o consumo de 
medicamentos por estes pacientes, observando as possíveis reações adversas a medicamentos (RAM), 
interações medicamentosas apresentadas e a presença de medicamentos de alto risco prescritos para 
este grupo etário. A pesquisa foi descritiva e transversal, com abordagem quantitativa, constituída por 
uma amostra de 65 pacientes, acompanhados através do Centro de Farmacovigilância do hospital, no 
período de agosto de 2009 a julho de 2010. Mais de 90% dos pacientes estavam sob polifarmácia, as 
possíveis RAM encontradas estavam mais relacionadas ao trato gastrintestinal e as interações foram mais 
frequentes com os medicamentos de ação cardiovascular. Dentro do contexto da farmacoepidemiologia, 
o profissional farmacêutico pode contribuir para a melhoria da qualidade de vida dos pacientes e evitar 
gastos desnecessários devido à terapêuticas errôneas e mal avaliadas.
Unitermos: Terceira Idade/uso de medicamentos. Polifarmácia. Medicamentos/reação adversa. Interação 
medicamentosa.
INTRODUCTION
With the advancement of medical care and improve-
ment of infrastructure and urban sanitation over the past 
few decades, the demographic pyramid of Brazil has un-
dergone significant changes in its structure. These changes 
are due to the rise in the over 60-year age-group, reduced 
birth and mortality rates, plus longer life expectancy at 
birth (OPAS, 2007).
In 2004, the elderly represented 9.0% of the total 
population of the country and mortality stood at 58.4% 
(OPAS, 2007). According to statistics from the World 
Health Organization (WHO), in 2025, Brazil is set to 
have approximately 32 million people aged 60 or older 
(Brazil, 1999).
With ageing, a number of systems and organs begin 
to fail, contributing to the emergence of chronic diseases 
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such as hypertension and Diabetes mellitus. Against this 
background, the elderly accounted for 9.5% of hospital 
admissions in the public health care system in 2005, and 
diseases of the circulatory, respiratory and digestive sys-
tems were the main causes of admissions (OPAS, 2007).
In the third age, pharmacokinetic changes are more 
apparent as a result of reduced intestinal absorption sur-
face, plasma proteins, and changes in liver and kidney 
function, which favor the emergence of problems during 
the therapy administered (Barradas, 2005).
Polypharmacy or polypharmacotherapy occurs 
when five or more medicines are used in association, when 
the patient uses a drug they do not require, or upon use of 
one drug to treat the adverse effects of another (Medeiros-
Souza et al., 2007).
On average, according to the Brazil’s National Treat-
ment Formulary and based on studies conducted in Cuba, 
seniors aged 65 to 69 years use 13.5 prescription drugs per 
year, while those over 80 years can use 18.2 medicines/
year. The most consumed drugs are antihypertensive drugs, 
analgesics, anti-inflammatory drugs, sedatives and gastroin-
testinal preparations (Brazil, 2008; Guerra et al., 2002).
The practice of polypharmacy is dangerous for 
patients, in particular for the elderly, because it favors 
the emergence of adverse drug reactions (ADR), side 
effects, drug interactions, longer hospital stay, iatrogenic 
disease and may also lead to complications that induce 
the patient’s death (Woor, Argüelles, 2007; Cedeño, et 
al., 2000).
Therefore, polypharmacy is a serious public health 
problem, which entails greater spending on public service 
health and medicines, and is not conducive to an improved 
quality of life of the population. It also hinders the process 
of access to drug treatment by the patient, which is an ad-
ded complication for elderly patients due to their reduced 
sensory and cognitive functions (Guerra et al., 2002).
The Study of Drug Use (SDU) aims to reduce the 
intensity of undesirable effects produced by drug inte-
ractions as well as other negative responses related to the 
use of medicines through the monitoring of marketing, 
distribution, prescription, dispensing and use of medicines 
in society (Bittencourt, Cruz, Castilho, 2004).
Within the context of pharmacovigilance and propo-
sals by pharmacotherapeutic follow-up studies, SDU for 
seniors seeks information to promote improved quality of 
life of patients and to provide data to devise pharmacothe-
rapeutic employee profiles and to elucidate the emergence 
of adverse reactions and other problems related to drugs 
(Muñoz et al., 2007; FAF, 2006).
According to the WHO (2005), the ADR are “all 
unwanted and harmful effect of a medicinal product which 
occurs at doses normally used for the treatment of a disease 
or the modification of physiological function”.
According to the Third Consensus of Granada on 
Problems related to Medicines (PRM) and Negative Ou-
tcomes associated to Medicines (RNM) (2007), the PRM 
occur when the use of medicines cause, or may cause, the 
appearance of negative outcomes associated with medi-
cation and health results in RNM are patient not suitable 
for the purpose of Pharmacotherapy, associated with the 
use or failure to use medicines.
In this vein, to better meet the needs arising in 
connection with the third age, Brazil’s National Congress 
through Legal Opinion 1.301 concerning proposed Law 
n° 57/2003, adopts provisions concerning the status of 
the elderly, as stipulated in article 2 °: The elderly person 
enjoys all the rights inherent to human beings, without pre‑
judice to the full protection of this law, ensuring them, by 
law or by other means, all opportunities and facilities for 
preservation of their physical and mental health as well as 
their moral, intellectual, spiritual and social improvement, 
under conditions of freedom and dignity (Brazil, 2003).
MATERIAL AND METHODS
A cross-sectional descriptive study with a quantita-
tive approach in a random convenience sample of patients 
was conducted between August 2009 and July 2010.
Elderly in-patients (aged 60) of the medical clinic 
and out-patients of the surgical philanthropic hospital 
Foundation Assistance of Paraíba (FAP) in Campina 
Grande-PB were followed using methods of pharma-
covigilance, where patient records were reviewed and 
interviews conducted with patients (active approach). The 
study was conducted at the Centre of Pharmacovigilance 
of the hospital, part of the network of Sentinel Hospitals 
of the National Agency of Sanitary Surveillance in Brazil.
The study was conducted by the pharmacovigilance 
group belonging to the institution, in partnership with the 
State University of Paraíba because the philanthropic te-
aching hospital is classified as medium-sized and has just 
one pharmacist who performs only the traditional activities 
of the hospital pharmacy.
For this monitoring, standard forms were employed to 
register variables related to clinical condition, personal de-
tails (age, gender, active diagnoses, length of stay), data on 
treatments employed and complaints presented by patients 
during hospitalization. Polypharmacy was considered for 
patients who used five or more concomitant medications.
Patients of both genders were included, irrespective 
of age, race or social class. Patients in a condition that 
hindered the collection of data, such as those intubated, 
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mechanically-ventilated, unconscious or in an intensive 
care unit (ICU), or whose data from medical records were 
insufficient to complete the questionnaire, were excluded 
from the study.
For the detection of possible ADR, the algorithm 
Naranjo et al. (1981) was used. The algorithm employs ten 
questions and yields a score for classification of causality 
of ADR. Comorbidities were differentiated when there 
was a possible diagnosis in the patient charts.
The physical condition of the patients was graded 
according to the American Society of Anesthesiologists 
(ASA), designed to provide a common terminology and 
facilitate the tabulation of statistical data. Classification 
matches: ASA I - normally healthy patient, ASA II - Pa-
tient with mild systemic disease, ASA III - Patient with 
severe systemic disease, ASA IV - Patient with severe 
systemic disease that threatens life, ASA V - moribund 
patient (death in 24 hours with or without surgery) (Lema, 
2002-modified).
For the classification of body mass index (BMI), the 
cut-off points defined by the World Health Organization 
(WHO 1997) were employed: eutrophic (18.5 – 24.9 kg/m²); 
overweight (25.0 – 29.9 kg/m²) and obese (≥ 30 kg/m²).
Diagnostic findings were grouped according to the 
chapters of the 10th edition of the international classifi-
cation of diseases (ICD 10) (WHO, 2003) and medicines, 
according to the Anatomical Therapeutic Chemical (ATC) 
Classification Index, indicated for use in SDU (Capellà, 
Laporte, 1993).
For classification of PRM, the criteria advocated 
by the Third Consensus of Granada (2007) were used. To 
determine the possible drug interactions found in the pres-
criptions, the Micromedex database and manual Stockley’s 
drug interactions manual (2009), were used.
The quantitative variables were subjected to 
epidemiologically-based statistical analysis by building 
tables with averages, standard deviations, minimum and 
maximum values, and absolute and relative frequencies, 
with the aid of EPI INFO 3.5.1.
According to Resolution nº 196/96 of Brazil’s 
National Health Council, a free and informed consent , 
explaining the conditions and purpose of the survey was 
signed by researcher and research subjects. The project 
was approved by the Committee of Ethics in Research 
of the State University of Paraiba under CAAE number 
4562.0.000.133-09.
RESULTS AND DISCUSSION
The sample comprised 65 patients, with 32 admitted 
to the surgical ward of the Outpatient clinic and 33 to the 
Medical Clinic. Sixty-seven patients were excluded becau-
se of lack of data from medical records. Table I contains 
clinical and personal data of patients.
Drug-related problems are common among elderly 
patients who are discharged from the hospital and are us-
ing several drugs for their chronic diseases. Examples of 
drug-related problems include contraindications, interac-
tions, adverse drug reactions and inefficacy of treatment 
(Ahmad et al., 2010).
Of patients, 64.6% were overweight or obese, cor-
roborating the report of Buzzachera et al. (2008), where 
predominantly females presented this morbidity in the 
treatment group. All patients stated absence or unaware-
TABLE I - Clinical and Personal Characteristics of Patients
Variables % - SD 
Gender  
Male 35.4% (n = 23) 
Female 64.6% (n = 42) 
Age (years) (mean ± standard 
deviation) 
72.47 ± 8.37y (minimum 
60, maximum 89) 
ASA*  
1 41.5% (n = 27) 
2 49.2% (n = 32) 
3 9.3% (n = 6) 
BMI*  
Eutrophic 35.4% (n = 23) 
Overweight 46.2% (n = 30) 
Obese 18.4% (n = 12) 
Length of hospital stay 
(days) (mean ± SD) 
7.21 ± 7.56 (minimum 1, 
maximum 51) 
Number of active Diagnoses 
(Mean ± SD) 
2.13 ± 1.06 (minimum 1, 
maximum 6) 
Number of medicines used 
(Mean ± SD) 





64.6% (n = 42) 
High 
ICU*
24.6% (n = 16) 
Death 10.8% (n = 7) 
Use of medicinal products before 
Hospitalization 
Yes – 100% 
Allergic to any medicine No – 100% 
Campina Grande, 2010. 
*ASA - American Society of Anesthesiologists; BMI – Body 
Mass Index; ICU – Intensive Care Unit
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ness of having an allergy to any drugs and all were already 
in use of a drug before the process of admission.
With respect to the number of medications adminis-
tered to each patient, 92.3% (n=60) of in-patients were un-
der polypharmacy. Polypharmacy, constituting a condition 
contributing to the emergence of adverse drug reactions 
(ADR), may have induced the possible reactions found in 
patients (Figure 1), as well as the relative length of stay 
(Medeiros-Souza et al., 2007). In the study by Ahmad et 
al. (2010), Amsterdam, the polypharmacy patients were 
rehospitalized more often.
The large number of associated drugs favors the 
emergence of adverse reactions and PRM/RNM, as 
verified by Correr et al. (2007), where 13.5% of the drugs 
used were inadequate and classified at high risk of RNM 
with regard to therapeutic safety. Similarly, Mosegui et 
al. (1999) observed that 17.0% of the drugs used by 634 
patients were unsuitable for the elderly and 15.5% had 
some drug interactions.
The 36 possible ADR found were related to the gas-
trointestinal tract, skin and the nervous system. Formiga, 
Jover and Mascaró (2001) found similar results in Spain 
regarding ADR, for emergence of complications during 
the hospital stay, but these differed as regards medicinal 
products administered.
In a study conducted in Germany, the drugs leading 
to ADR were used for hypertension, depression and in-
flammatory processes, and often involved use of herbal 
drugs containing Ginkgo biloba and Hypericum perfora‑
tum (Jeschke et al., 2010).
According to Routledge, O’Mahony and Woodhouse 
(2003), ADR are the cause of 6.7% of hospital admissions in 
the United States and 0.32% of ADR are fatal in patients. In 
the present study, no deaths were related to possible ADR.
The medicines used by patients suspected of cau-
sing ADR are shown in Figure 2. Table II contains the 
medicines administered during the hospital stay, ordered 
according to the Anatomical Therapeutic Chemical Code.
Of the 123 medicines reported, Furosemide (12.2%), 
Glibenclamide (10.6%) and Captopril (6.5%) were the most 
prescribed medicines,, due to the large number of patients 
with hypertension (32.3%-n = 40), a chronic disease increa-
singly present in the elderly and young adults (Blasco, 2008). 
The high number of diagnoses of anemia (19.6%-n = 21), 
diabetes and neoplasms was also noted, both with n=9 (7.3%).
The high rate of prescription of drugs that act on the 
cardiovascular, central nervous and digestive systems was 
also observed by Teixeira et al. (2008). Diagnostic findin-
gs during hospitalization are listed in Table III, ordered 
according to the chapters of ICD-10.
A total of 63 potential drug interactions were found 
on patient prescriptions, most frequent of which are shown 
in Table IV.
Acetylsalicylic acid (Aspirin) decreases diuretic 
action and increases the risk of digitalis poisoning, me-
FIGURE 1 - Possible ADR found in the 65 patients studied. 
Campina Grande, 2010.
FIGURE 2 - Drugs suspected of causing ADR. Campina Grande, 
2010.
TABLE II - Anatomical therapeutic chemical classification of 
medicinal products in accordance with the ATC
ATC 
level 1 
Classification N % 
A Digestive Tract and metabolism 42 34.1
B Blood and Blood-forming organs 02 1.6
C Cardiovascular system 49 39.8
H Hormones, except sexual and insulin 01 0.8
J Systemic Anti-infective agents 11 8.9
N Nervous System 17 13.8
P Antiparasitics 01 0.8
Total  123 100.0
Campina Grande, 2010. 
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tamizole decreases hypoglycemic effects, while some 
antihypertensive and anti-emetic agents, as well as con-
current use of inhibitors of angiotensin converting enzyme 
with potassium-sparing, increase the risk of hyperkalemia 
(Ibáñez et al., 2008; José et al., 2008).
The most common problems related to drugs (PRM) 
s, according to the Third Consensus of Granada (2007), 
were those concerning contraindications, double thera-
peutic classes, and possible drug interactions likely to 
cause ADR.
Due to the potential of PRM to cause negative res-
ponses associated with medication (RNM), they represent 
a serious public health problem and should be avoided, 
since they further undermined the quality of life of hos-
pitalized elderly patients in Spain (Santamaría-Pablos et 
al., 2009; Garcia et al., 2008).
TABLE III - Classification of 124 active diagnoses according to chapters of ICD 10
Chapter ICD 10 Classification n % 
I Infectious and parasitic diseases 08 6.5%
II Neoplasms 10 8.1%
III 
Diseases of blood and blood-forming organs and certain disorders 
involving immune mechanism 
22 17.7%
IV Endocrine, nutritional and metabolic diseases 09 7.3%
V Mental and behavioural disorders 03 2.4%
VIII Diseases of ear and mastoid 01 0.8%
IX Diseases of circulatory system 56 45.2%
X Respiratory tract Diseases 04 3.2%
XI Digestive tract Diseases 04 3.2%
XIII 
Disease of Musculoskeletal system and 
connective tissue
05 4.0%
XIV Diseases of genitourinary system 02 1.6%
Total  124 100.0%
Campina Grande, 2010. 
TABLE IV – Most frequent possible drug interactions in prescriptions of elderly patients
Drug Interaction n % Possible Effect
Aspirin + Furosemide 01 3.3% Decreases diuretic action
Captopril + Digoxin 03 10.0% Increases risk of digitalis poisoning
Captopril + Metamizole 04 13.3% Decreases ACE* inhibitor action
Captopril + Spironolactone 03 10.0% Increases risk of hyperkalemia
Caverdilol + Spironolactone 01 3.3% Increases risk of hyperkalemia
Clonidine + Diazepam 01 3.3% Increases risk of accident
Digoxin + Furosemide 04 13.3% Increases risk of digitalis poisoning
Digoxin + Hydrochlorothiazide 01 3.3% Increases risk of digitalis poisoning
Insulin + Furosemide 02 6.7% Decreases hypoglycemic effect
Metamizole + Glibenclamide 03 10.0% Decreases hypoglycemic effect
Metamizole + Insulin 04 13.3% Decreases hypoglycemic effect
Metamizole + Metoclopramide 03 10.0% Increases rate of analgesic absorption
Total 30 100.0%
Source: Micromedex Database, Stockley’s Drug Interactions (2009) - Campina Grande, 2010 
*ACE - angiotensin converting enzyme
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The prescribed drugs having a potentially high risk 
for elderly patients are cited in Table V.
CONCLUSIONS
Even during short periods of hospitalization, more 
careful assessment is required when making out prescrip-
tions in order to prevent drug-related complications, which 
have a negative impact on the health of elderly patients. 
This is especially important in this group which is psycho-
logically vulnerable and often in an unfamiliar environ-
ment without the presence of relatives or acquaintances.
The Adverse Drugs Reactions and drug interactions 
found were denoted possible, since the study was not a 
follow-up on drug use, for which an appropriate methodol-
ogy would be required.
The pharmacist as a health promoter must participate 
in the clinical monitoring, assessment and guidance of the 
therapy prescribed, interacting with others professionals 
toward improving the quality of life of this patient group.
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